

Cover Story
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
In Brief


Trending Stories
- Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages